Celldex Therapeutics Inc. (CLDX)
Celldex Therapeutics Inc. (CLDX) Stock Price, Analysis & Data
| Cours acheteur | 36.43 |
| Capitalisation boursière | 3.27B |
| Chiffre d’affaires (ttm) | 158K |
| Résultat net (ttm) | -300.55M |
| Bêta | 0.84 |
| EPS (ttm) | -4.35 |
| Ratio P/E (ttm) | n/a |
| P/E prévisionnel | -10.02 |
| P/B (ttm) | 4.58 |
| P/S (ttm) | 20725.83 |
| Earnings Date | Nov 9, 2026 |
| Cours vendeur | 48.47 |
| Volume | 249,041 |
| Volume moy. (20D) | 1,032,000 |
| Ouverture | 42.51 |
| Clôture précédente | 41.79 |
| Fourchette du jour | 41.73 - 43.20 |
| Intervalle de 52 semaines | 20.37 - 45.14 |
| Analyste | n/a |
| Objectif de prix | n/a |
| Dividendes | n/a |
| Date ex-dividende | n/a |
À propos de CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that spe...
Performance financière
En 2025, le chiffre d’affaires de Celldex Therapeutics s’élevait à 1.54M, soit une baisse de -77.99% par rapport aux 7.02M de l’année précédente. Le bénéfice s’élevait à -258.76M, soit une hausse de 63.91%.
États financiersSurprise sur les résultats
Les analystes prévoient un chiffre d’affaires de ... Passer à l’offre supérieure
1 semaine il y a · Simply Wall St.
Celldex Therapeutics (CLDX) Could Be 130% Undervalued After Second Quarter ResultsCelldex Therapeutics (CLDX) released its second quarter 2026 results on 6 August, reporting very limited revenue and a wider net loss. This places the stock’s recent strength in sharper focus for inve...
1 semaine il y a · Simply Wall St.
Is Celldex Therapeutics’ (CLDX) Growing Losses With Minimal Revenue a Strategic Bet or Structural Concern?Celldex Therapeutics, Inc. recently reported second-quarter 2026 results, with revenue falling to US$0.022 million and net loss widening to US$73.5 million, while loss per share from continuing operat...
1 semaine il y a · Simply Wall St.
Celldex Therapeutics (CLDX) Stock Trades At A Premium Despite A 102% ReturnCelldex Therapeutics stock has more than doubled over the past year, yet its broader valuation checks lean expensive rather than cheap, which raises questions about how much of its pipeline story is a...
1 semaine il y a · Simply Wall St.
What Is Celldex Therapeutics (CLDX) Signaling With Its Mixed Pipeline Update?Celldex Therapeutics (NasdaqCM:CLDX) reported updated clinical pipeline data, including positive Phase 1 results for bispecific antibody CDX-622. The company outlined progress on ongoing Phase 3 studi...
